3-indazolyl-4-pyridylisothiazoles

Details 3-indazolyl-4-pyridylisothiazoles 3-indazolyl-4-pyridylisothiazoles

2011-04-26

2011-04-26

Morris, Patricia L (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S271100

Reexamination Certificate

active

07932274

ABSTRACT:
The present invention provides 3-indazoyl-4-pyridylisothiazoles or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and methods of using the same, as well as processes for preparing the same, and intermediates thereof.

REFERENCES:
patent: 4075001 (1978-02-01), Gibbons
patent: 5538939 (1996-07-01), Muenster et al.
patent: 2006/0194807 (2006-08-01), Cosford
patent: 0129407 (1984-12-01), None
patent: 1247810 (2002-10-01), None
patent: WO 00/24739 (2000-05-01), None
patent: 2007061909 (2007-05-01), None
patent: WO 2008/103185 (2008-08-01), None
patent: 2008128951 (2008-10-01), None
Slassi, Abdelmalik et al., Recent Advances in Non-Competitive mGlu5 Receptor Antagonists and their Potential Therapeutic Applications,Current Topics in Medicinal Chemistry, 2005, 5, pp. 897-911.
De Paults et al: Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation on the metabotropic glutamate-5 receptor in rat cortical astrocytes, Journal of Medicinal Chemistry, American Chemical Society, vol. 49, Jan. 1, 2006, pp. 3332-3344.

Affiliated with

Also associated with

Rating

3-indazolyl-4-pyridylisothiazoles does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 3-indazolyl-4-pyridylisothiazoles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-indazolyl-4-pyridylisothiazoles will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2717460